Home › Upcoming votes › Bio-Techne Corporation
This meeting took place on September 23, 2026. Bio-Techne Corporation reported the official results on Form 8-K, filed September 23, 2026 (read it on EDGAR); they are listed below. How funds voted appears on the company page after funds file Form N-PX, by August 31 after the proxy season ends on June 30.
Read the proxy statement on EDGARBio-Techne Corporation: past votes
As listed in Bio-Techne Corporation’s proxy statement, with the board’s recommendation on each item. The company has filed 2 sets of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | MERGER AGREEMENT PROPOSAL | Board | For | — |
| 2 | NON-BINDING COMPENSATION ADVISORY PROPOSAL | Board | For | — |
| 3 | ADJOURNMENT PROPOSAL Adjournment |
Board | For | — |
From Bio-Techne Corporation’s Form 8-K, filed November 5, 2025, for the meeting held October 30, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| 1. The shareholders voted to set the number of directors at nine | 99.7% | — |
| Elect Director: Robert V. Baumgartner | 95% | Elected |
| Elect Director: Julie L. Bushman | 97% | Elected |
| Elect Director: John L. Higgins | 96% | Elected |
| Elect Director: Kim Kelderman | 99.2% | Elected |
| Elect Director: Joseph D. Keegan | 97% | Elected |
| Elect Director: Alpna Seth | 96% | Elected |
| Elect Director: Rupert Vessey | 98% | Elected |
| Elect Director: Judith Klimovsky | 98% | Elected |
| Elect Director: Amy Herr | 99.0% | Elected |
| 3. A non-binding resolution approving the compensation of the Company's named executive officers, as described in the Proxy Statement | 72% | Approved |
| 4. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2026 | 98% | Approved |
The five managers that reported the most shares voted at Bio-Techne Corporation’s October 30, 2025 meeting, from their Form N-PX filings. This is how they voted then; it says nothing about how they will vote this time. Every manager’s vote.
| Item | Vanguard | BlackRock | T. Rowe Price | Invesco | ATLANTA CAPITAL MANAGEMENT CO L L C |
|---|---|---|---|---|---|
| 1. The shareholders voted to set the number of directors at nine | For | For | For | For | — |
| Elect Director: Robert V. Baumgartner | For | For | For | For | — |
| Elect Director: Julie L. Bushman | For | For | For | For | — |
| Elect Director: John L. Higgins | For | For | For | For | — |
| Elect Director: Kim Kelderman | For | For | For | For | — |
| Elect Director: Joseph D. Keegan | For | For | For | For | — |
| Elect Director: Alpna Seth | For | For | For | For | — |
| Elect Director: Rupert Vessey | For | For | For | For | — |
| Elect Director: Judith Klimovsky | For | For | For | For | — |
| Elect Director: Amy Herr | For | For | For | For | — |
| 3. A non-binding resolution approving the compensation of the Company's named executive officers, as described in the Pr | For | Mixed | Mixed | Against | For |
| 4. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending | For | For | For | For | — |
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Merger Agreement Proposal | 99.0% | — |
| Non-Binding Compensation Advisory Proposal: | 21% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the filing automatically and checked against the proxy’s own item count and voting card; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.